bs-0664R [Primary Antibody]
HMGB1 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: HMGB1

Immunogen Range: 75-170/215


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 3146

Swiss Prot: P09429

Source: KLH conjugated synthetic peptide derived from human HMGB1

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

DNA binding proteins that associates with chromatin and has the ability to bend DNA. Binds preferentially single-stranded DNA. Involved in V(D)J recombination by acting as a cofactor of the RAG complex. Acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS). Heparin-binding protein that has a role in the extension of neurite-type cytoplasmic processes in developing cells (By similarity).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 25


Cross Reactive Species: Human
Mouse
Rat

Predicted Cross Reactive Species: Cow

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Zhao, Lu, et al. "The high mobility group box 1 protein of< i> Sciaenops ocellatus</i> is a secreted cytokine that stimulates macrophage activation." Developmental & Comparative Immunology 35.10 (2011): 1052-1058.Read more>>
  • Jiang, W., et al. "Curculigoside A attenuates experimental cerebral ischemia injury< i> in vitro</i> and< i> vivo</i>." Neuroscience 192 (2011): 572-579.Read more>>
  • Rui, Zhang, et al. "Omega-3 polyunsaturated fatty acids inhibit the increase in cytokines and chemotactic factors induced in vitro by lymph fluid from an intestinal ischemia-reperfusion injury model." Nutrition (2014).Read more>>
  • Wang, Xin‑Jun, et al. "Clinical and prognostic significance of high-mobility group box-1 in human gliomas." Experimental and Therapeutic Medicine.Read more>>
  • Sun, Shanping, et al. "High mobility group box-1 and its clinical value in breast cancer." OncoTargets and Therapy 8 (2015): 413.Read more>>
  • Li, Yuan-bo, et al. "Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression." Molecular and Cellular Biochemistry: 1-10.Read more>>
  • Li, Guofu, et al. "The neutrophil elastase inhibitor, sivelestat, attenuates sepsis-related kidney injury in rats." International Journal of Molecular Medicine 38.3 (2016): 767-775.Read more>>
  • He et al. The effects of n-3 PUFA and intestinal lymph drainage on high-mobility group box 1 and Toll-like receptor 4 mRNA in rats with intestinal ischaemia-reperfusion injury. (2012) Br.J.Nut. 108:883-92Read more>>
  • Wang et al. Clinical and prognostic significance of high-mobility group box-1 in human gliomas. (2015) Exp.Ther.Me. 9:513-518Read more>>
  • Qiao et al. Effect of different 1, 25-(OH)2D3 doses on high mobility group box1 and toll-like receptors 4 expression in lung tissue of asthmatic mice. (2015) Int.J.Clin.Exp.Med. 8:4016-23Read more>>
  • Sun et al. Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis. (2016) Med.Sci.Monit. 22:2105-12Read more>>
  • Hong et al. Luteolin Treatment Protects against Renal Ischemia-Reperfusion Injury in Rats. (2018) Mediators.Inflamm. 2017:9783893Read more>>
  • Xiang et al. Glycyrrhizin suppresses the expressions of HMGB1 and relieves the severity of traumatic pancreatitis in rats. (2014) PLoS.One. 9:e115982Read more>>
  • Shi Q et al. Polychlorinated biphenyl quinone-induced signaling transition from autophagy to apoptosis is regulated by HMGB1 and p53 in human hepatoma HepG2 cells. Toxicol Lett. 2019 May 15;306:25-34. Read more>>
  • Yuan FH et al. microRNA‐30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS‐1 in rats with sepsis. J Cell Physiol. 2019 Apr 10. Read more>>
  • Diao S et al. IGF2 enhanced the osteo‐/dentinogenic and neurogenic differentiation potentials of stem cells from apical papilla. J Oral Rehabil. 2019 Jul 10. Read more>>
  • Feng B et al. Enhancing Triple Negative Breast Cancer Immunotherapy by ICG‐Templated Self‐Assembly of Paclitaxel Nanoparticles. Advanced Functional Materials,2019 1906605. Read more>>
  • Chen Y et al. Dendritic cells-derived interferon-1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis. Cell Death Dis. 2020 Jun 2;11(6):414.Read more>>
  • Hongzhong Cheng. et al. Circular RNA circLPAR3 Facilitates Esophageal Squamous Cell Carcinoma Progression Through Upregulating HMGB1 via Sponging miR-375/miR-433. Oncotargets Ther. 2020; 13: 7759C7771Read more>>
  • Xuting Liu. et al. Amorphous silica nanoparticles induce inflammation via activation of NLRP3 inflammasome and HMGB1/TLR4/MYD88/NF-kb signaling pathway in HUVEC cells. J Hazard Mater. 2021 Feb;404:12405Read more>>
  • Lei Chen. et al. Circ_0032821 Facilitates Gastric Cancer Cell Proliferation, Migration, Invasion and Glycolysis by Regulating MiR-1236-3p/HMGB1 Axis. Cancer Manag Res. 2020; 12: 9965C9976Read more>>
  • Tian Zhang. et al. Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid-Derived Suppressor Cells and Heightening Immunogenicity. 2021 May 13Read more>>
  • Zhen-Han Feng. et al. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle. Acta Biomater. 2021 OcRead more>>
  • Yuting Shen. et al. Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation. Acs Nano. 2021;XXXX(XXX):XXX-XXXRead more>>
  • Tao He. et al. A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence. ACTA PHARM SIN B. 2022 SepRead more>>
  • Qingfei Zhang. et al. Hierarchical Microparticles Delivering Oxaliplatin and NLG919 Nanoprodrugs for Local Chemo-immunotherapy. ACS APPL MATER INTER. 2022;XXXX(XXX):XXX-XXXRead more>>
  • Songlin Gong. et al. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence. SMALL. 2022 Nov;:2107061Read more>>
  • Zhu Lipeng. et al. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy. J NANOBIOTECHNOL. 2022 Dec;20(1):1-24Read more>>
  • Xiang Ao. et al. Lavender essential oil accelerates lipopolysaccharide-induced chronic wound healing by inhibiting caspase-11-mediated macrophage pyroptosis. KAOHSIUNG J MED SCI. 2023 FebRead more>>
  • Xiahong Tang. et al. Hypoxic preconditioned mesenchymal stem cells ameliorate rat brain injury after cardiopulmonary resuscitation by suppressing neuronal pyroptosis. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2023 MayRead more>>
  • Sancar Serap. et al. A Cicada Antimicrobial Peptide, Cryptonin, Exhibits Potent Antitumor Activity by Necrosis on Human Melanoma Cells. INT J PEPT RES THER. 2023 Jul;29(4):1-1Read more>>
  • Farrag Eman A. E.. et al. Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE/HMGB-1 signaling pathway. SCI REP-UK. 2023 Jul;13(1):1-13Read more>>
  • Wangxian Fu. et al. A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cells. BIOMATERIALS. 2024 Mar;305:122444Read more>>
VALIDATION IMAGES

Lane 1: Mouse Macrophages probed with Rabbit Anti-HMGB1 Polyclonal Antibody, Unconjugated (bs-0664R) at 1:300 overnight at 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:5000 for 90 min at RT.


Formalin-fixed and paraffin embedded human endometrium carcinoma labeled Anti-HMGB1 Polyclonal Antibody, Unconjugated (bs-0664R) at 1:200, followed by conjugation to the secondary antibody and DAB staining


Human HepG2 cell lysates probed with Rabbit Anti-HMGB1 Polyclonal Antibody, PE-Cy5 conjugated (bs-0664R-PE-Cy5) (green) at 1:20 for 30 minutes followed compared to unstained cells (blue) and PE-Cy5 isotype control bs-0295P-PE-Cy5(orange).


HL-60 cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20℃, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with HMGB1 Polyclonal Antibody(bs-0664R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).


HepG2 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (HMGB1) polyclonal Antibody, Unconjugated (bs-0664R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.